What is a primary concern when prescribing Zyprexa for a patient?

When prescribing Zyprexa (olanzapine), a primary concern is the elevation of lipids and glucose. Zyprexa is an atypical antipsychotic that has been associated with metabolic side effects, particularly weight gain, hyperlipidemia, and hyperglycemia. These effects can lead to an increased risk of metabolic syndrome and cardiovascular disease, which are significant health concerns for patients, particularly those with pre-existing conditions or risk factors for diabetes and heart disease.

Understanding the metabolic profile of atypical antipsychotics like Zyprexa is crucial for monitoring patient health, as the weight gain can be substantial and may not be reversible upon discontinuation of the medication. Regular screening for glucose and lipid levels is recommended for patients on Zyprexa to manage these risks proactively.